Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT2152 + palbociclib ± sasanlimab in advanced ccRCC
NCT05935748Phase 2Terminated
- Sponsor
- NiKang Therapeutics
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NKT2152 (NiKang Therapeutics) in clear cell renal cell carcinoma (ccRCC), sponsored by NiKang Therapeutics. Started Jul 2023; status: terminated.
02
Drugs
NKT2152 (NiKang Therapeutics)
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05935748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935748.